Edesa Biotech (EDSA) Receivables - Net (2013 - 2026)

Edesa Biotech has disclosed Receivables - Net across 14 years of filings, most recently posting $228051.0 for Q2 2026.

• In Q2 2026, Receivables - Net fell 20.47% year-over-year to $228051.0; the TTM figure through Jun 2026 stood at $228051.0 (down 20.47% YoY), while the FY2025 annual figure was $642866.0, up 137.3% from the prior year.
• Receivables - Net came in at $228051.0 for Q2 2026 at Edesa Biotech, down from $431325.0 in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $1.4 million in Q2 2022 to a low of $42866.0 in Q2 2023.
• Average Receivables - Net over 5 years is $573736.9, with a median of $431325.0 recorded in 2025.
• Year-over-year, Receivables - Net tumbled 96.95% in 2023 and soared 2114.32% in 2024.
• Over 5 years, Receivables - Net stood at $125477.0 in 2022, then soared by 492.59% to $743569.0 in 2023, then slumped by 52.84% to $350639.0 in 2024, then advanced by 23.01% to $431325.0 in 2025, then plunged by 47.13% to $228051.0 in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $228051.0 in Q2 2026, $431325.0 in Q4 2025, and $642866.0 in Q3 2025.